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Abstract
Background
A recent comprehensive report on healthcare quality in Italy published by the Organization
of Economic Co-operation and Development (OECD) recommended that regular monitoring
of quality of primary care by means of compliance with standards of care for chronic dis-
eases is performed. A previous ecological study demonstrated that compliance with stan-
dards of care could be reliably estimated on regional level using administrative databases.
This study compares estimates based on administrative data with estimates based on GP
records for the same persons, to understand whether ecological fallacy played a role in the
results of the previous study.
Methods
We compared estimates of compliance with diagnostic and therapeutic standards of care
for type 2 diabetes (T2DM), hypertension and ischaemic heart disease (IHD) from adminis-
trative data (IAD) with estimates from medical records (MR) for the same persons registered
with 24 GP’s in 2012. Data were linked at an individual level.
Results
32,688 persons entered the study, 12,673 having at least one of the three diseases accord-
ing to at least one data source. Patients not detected by IAD were many, for all three condi-
tions: adding MR increased the number of cases of T2DM, hypertension, and IHD by +40%,
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+42%, and +104%, respectively. IAD had imperfect sensitivity in detecting population com-
pliance with therapies (adding MR increased the estimate, from +11.5% for statins to
+14.7% for antithrombotics), and, more substantially, with diagnostic recommendations
(adding MR increased the estimate, from +23.7% in glycated hemoglobin tests, to +50.5%
in electrocardiogram). Patients not detected by IAD were less compliant with respect to
those that IAD correctly identified (from -4.8 percentage points in proportion of IHD patients
compliant with a yearly glycated hemoglobin test, to -40.1 points in the proportion of T2DM
patients compliant with the same recommendation). IAD overestimated indicators of compli-
ance with therapeutic standards (significant differences ranged from 3.3. to 3.6 percentage
points) and underestimated indicators of compliance with diagnostic standards (significant
differences ranged from -2.3 to -14.1 percentage points).
Conclusion
IAD overestimated the percentage of patients compliant with therapeutic standards by less
than 6 percentage points, and underestimated the percentage of patients compliant with
diagnostic standards by a maximum of 14 percentage points. Therefore, both discussions
at local level between GP’s and local health unit managers and discussions at central level
between national and regional policy makers can be informed by indicators of compliance
estimated by IAD, which, based on those results, have the ability of signalling critical or
excellent clusters. However, this study found that estimates are partly flawed, because a
high number of patients with chronic diseases are not detected by IAD, patients detected
are not representative of the whole population of patients, and some categories of diagnos-
tic tests are markedly underrecorded in IAD (up to 50% in the case of electrocardiograms).
Those results call to caution when interpreting IAD estimates. Audits based on medical
records, on the local level, and an interpretation taking into account information external to
IAD, on the central level, are needed to assess a more comprehensive compliance with
standards.
Introduction
A recent comprehensive report on healthcare quality in Italy published by the Organization
of Economic Co-operation and Development (OECD) recommended that regular monitoring
of quality of primary care by means of compliance with standards of care for chronic diseases
is performed Italian National Healthcare System (NHS). Indeed, strengthening the national
quality governance model on this sector of health care is a strategic objective in an ageing pop-
ulation, with an expected growing burden of chronic conditions. In the report, smarter pay-
ment systems for general practitioners that reward quality are advocated for, with specific
reference to compliance with standards of care for chronic conditions [1].
However, measuring compliance with standards of care for chronic diseases is a challenging
task for the Italian NHS [2]. Italian administrative databases (IAD) are available to the NHS
uniformly from the whole country, and are the natural candidate data source. Unfortunately
their use is hampered by two problems: accuracy in identifying patients who have a chronic
disease, and accuracy in detecting compliance.
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As for the first problem, the data items collected in IAD do not allow direct identification of
patients with chronic conditions. Indeed, diagnoses performed in an outpatient setting are not
collected in IAD, and this is generally the case when a chronic disease is diagnosed [3]. In Italy
every adult patient is entitled to choose a general practitioner (GP), and specialist care can be
requested to the NHS by patients only upon referral by their GPs. GP’s soon become aware if a
chronic disease is diagnosed in their patients. Primary care medical records (MR) rather than
IAD may be the right source of information to correctly identify patients having a chronic
disease.
On the other hand, for the second problem, compliance with standards of care may go
undetected both by IAD and by MR. Over-the-counter purchase of prescribed drugs is not
recorded in IAD, and drug prescriptions issued by specialists are not recorded by GPs. Diag-
nostic tests ordered by GPs or specialists are only recorded by IAD if they are performed in
facilities belonging to, or contracted by, the NHS. This may fail to happen when access to such
facilities is perceived as slow or cumbersome by patients and tests are performed outside the
NHS system. Diagnostic exams are recorded in the MR either if GPs are the prescribers or if
patients themselves provide the result to their GPs, since there is no automatic transmission
of test results in place in Italy. Ordering of diagnostic tests may more often be done by a spe-
cialist for more severe patients, or when the local organization of the healthcare system fails to
encourage patients to access primary rather than secondary care. Hence sensitivity of MR in
detecting diagnostic tests depends both on patient-level and on geographic-level characteristics
[2].
For the reasons provided above, it was unclear whether compliance with standards of care
in a population of patients with chronic diseases could be reliably estimated using IAD and, as
a consequence, could be used to inform discussions on quality improvement and accountabil-
ity on a local and central level. It was however evident that comparison with primary care MR
had a chance to provide more knowledge on these questions [2,3,4,5].
In previous studies, case-finding strategies in IAD have been developed and validated [3],
and compliance with standards of care measured on those patients has been compared with
indicators obtained from a database of MR [2]. The results were encouraging, because esti-
mates were very similar across the two data sources. However, the comparison was an ecologi-
cal study, and many questions remained. It was not known whether the sample of patients
detected by IAD was representative of the true set of patients with the disease, or rather
patients not detected by IAD had different values of compliance. This could have combined
with incompleteness of both IAD and MR in detecting actual compliance, to provide a falsely
reassuring similarity between estimates.
The MATRICE Project, started by Italian National Agency for Regional Health Systems in
2011, aimed to assess in a more comprehensive way the validity of IAD as a data source to
monitor quality of health care for chronic diseases. MATRICE obtained from the National
Authority for Personal Data Protection permission to link IAD and MR of a large sample of
patients. In this study we could therefore compare compliance with standards of care for type
2 diabetes mellitus (T2DM), hypertension and ischaemic heart disease (IHD) using both data
sources, at the individual level.
Methods
Study design
For each person in the study population we searched both IAD and MR to determine whether
they had each disease and whether they received care compliant with our standards. Based on
previous study, we considered MR to be a gold standard for the presence of each disease [4,5].
Monitoring compliance with standards of care for chronic diseases in Italy
PLOS ONE | https://doi.org/10.1371/journal.pone.0188377 December 12, 2017 3 / 18
Electrocardiogram; EITHER, the individual-level
variable that measures compliance with a
recommendation using either MR or IAD; GP,
general practitioner; IAD, Italian Administrative
Databases; ICSO, Italian coding system for
outpatient services; IHD, Ischaemic heart disease;
LHU, Local Health Unit, the local organization of the
NHS; MR, Medical Records: the primary care
medical records of the 24 GP’s whose patients
entered the study; NHS, National Health Service;
OECD, Organization of Economic Co-operation and
Development; SIMG, National College for General
Practitioners: the Italian scientific society of
General Practitioners; T2DM, Type 2 Diabetes
Mellitus.
Based on the arguments in the Introduction, we considered that neither IAD nor MR had
complete information on compliance, so we assessed concordance among the two variables, in
the whole study population. To assess concordance among measures of indicators, and repre-
sentativeness of the patients that IAD correctly identified as having the disease, we compared
the indicators (proportion of patients who were compliant) in several subpopulations (patients
with the disease according to IAD, patients with the disease according to MR, patients that
IAD correctly identified as having the disease, patients not detected by IAD, patients that IAD
only classified as having the disease) using to detect compliance in turn IAD, MR and either of
the two sources.
See the subsection “Study variables” below for more details on how the variables were
defined, and the subsection “Data analysis” for more details on the statistical analysis.
Setting
From the point of view of organization of health care, Italy is divided into 21 regions, and each
region is divided in geographic subareas (on average 10 per region). Health care for the popu-
lation in each area is managed by organizations called Local Health Units (LHU). LHUs collect
administrative data on the health care they provide to their inhabitants which together form
the basis of the IAD.
A sample of 25 GPs belonging to five regions was initially recruited in this study. Three
regions were in the North (Lombardy, Veneto, Emilia-Romagna), one in the Center (Tuscany)
and one in the South (Puglia). The GPs were equally distributed among the five regions, and
all the GP’s of the same region belonged to the same LHU.
Standards of care and indicators of compliance
A panel of experts in organization of primary care services, epidemiologists and clinicians
selected clinical guidelines for T2DM, hypertension and IHD which were expected to be easy
to monitor on IAD. The result is depicted in Table 1: six recommendations for annual diag-
nostic follow-up and treatment with four drug classes were chosen, each applying to one or
more of the three conditions, totalling 18 recommendations. Each recommendation is labelled
with the name of the scientific society who published it, and with its grade and level [6].
Based on the recommendations, 18 indicators were chosen, each measuring the proportion
of patients with the specific disease who were compliant with the corresponding recommenda-
tion during the observation year. The indicators are listed in Box 1.
Data sources
Italian administrative databases (IAD). The main components of IAD are the following
tables
• Inhabitant registry (PERSON) is the list of subjects who live in a defined geographical area,
recorded with gender, date of birth, date of entry, date of exit, identifier of the chosen GP;
• Hospital discharge records (HOSP) is the table of hospital discharge records reimbursed by
the healthcare system, recorded with up to six diagnosis codes and up to six procedure codes
in ICD9CM
• Exemption registry (EXE) is the table of disease-specific exemptions from co-payment to the
healthcare system, recorded with a disease code which is a truncated ICD9CM code
• Drug dispensing registry (DRUGS) is the table of drugs dispensed by community or hospital
pharmacies free of charge or upon co-payment. Drugs are coded with a specific Italian
Monitoring compliance with standards of care for chronic diseases in Italy
PLOS ONE | https://doi.org/10.1371/journal.pone.0188377 December 12, 2017 4 / 18
Table 1. Standards of care, with levels and grades of recommendation. SID: Italian Diabetes Society. ESC/EASD: European Society of Cardiology and
European Association for the Study of Diabetes. ESH/ESC: European Society of Hypertension and European Society of Cardiology. ACC/AHA: American
Cardiology Association and American Heart Association. A symbol * means that the recommendation only applies when the condition is at a high level of
severity. Diagnostic tests are recommended once per year, except HbA1c for T2DM which is recommended twice a year.
Guideline type Recommendation in the guideline T2DM Hypertension IHD
Therapeutic Statins level I, grade A (SID) Level IIa, grade B (ACC/AHA)
Beta-blockers Level I, grade A (ACC/AHA) *
ACE inhibitors Level I, grade A (ACC/AHA) *
Antithrombotics Level I, grade A (ACC/AHA)
Diagnostic Microalbuminuria test level VI, grade B (SID) level I, grade B (ESH/ESC)
Glycated hemoglobin (HbA1c) tests level VI, grade B (SID) level I, grade B (ESH/ESC) Level I, grade A (ESC/EASD)
Lipid profile level III, grade B (SID) (ESH/ESC) Level III, grade B (ACC/AHA)
Clearence/creatinine test level VI, grade B (SID) level I, grade B (ESH/ESC)
Electrocardiogram(ECG) level I, grade B (ESH/ESC) *
Eye exam level III, grade B (SID) level IIa, grade C (ESH/ESC)
* the recommendation only applies when the condition is at a high level of severity
https://doi.org/10.1371/journal.pone.0188377.t001
Box 1. Indicators of compliance with standards of care during a year of follow-up. ATC: Anatomical
Therapeutic Chemical classification system for drugs. ICSO: Italian coding system for outpatient services.
Therapies
Proportion of patients with T2DM with at least two records of statins during the year (ATC: C10*)
Proportion of patients with IHD treated with at least two records of statins during the year (ATC: C10*)
Proportion of patients with IHD treated with at least two records of beta-blockers during the year (ATC:
C07*)
Proportion of patients with IHD treated with at least two records of ACE inhibitors during the year (ATC:
C09*)
Proportion of patients with IHD treated with at least two records of antithrombotics during the year (ATC:
B01A*)
Diagnostic follow-up
Proportion of patients with T2DM with at least a microalbuminuria test (ICSO: 90.33.4) during the year
Proportion of patients with hypertension with at least a microalbuminuria test (ICSO: 90.33.4) during the
year
Proportion of patients with T2DM with at least two tests of glycated emoglobin (ICSO: 90.28.1) during the
year
Proportion of patients with hypertension with at least a glycated emoglobin test (ICSO: 90.28.1) during the
year
Proportion of patients with IHD with at least a glycated emoglobin test (ICSO: 90.28.1) during the year
Proportion of patients with T2DM with at least a test of lipid profile (ICSO: 90.14.3 and 90.14.1 and 90.43.2)
during the year
Proportion of patients with hypertension with at least a test of lipid profile (ICSO: 90.14.3 and 90.14.1 and
90.43.2) during the year
Proportion of patients with IHD with at least a test of lipid profile (ICSO: 90.14.3 and 90.14.1 and 90.43.2)
during the year
Proportion of patients with T2DM with at least a test of clearence/creatinine (ICSO: 90.16.3 or 90.16.4)
during the year
Proportion of patients with hypertension with at least a test of clearence/creatinine (ICSO: 90.16.3 or
90.16.4) during the year
Proportion of patients with hypertension with at least an electrocardiogram (ICSO: 89.52) during the year
Proportion of patients with IHD with at least an electrocardiogram (ICSO: 89.52)during the year
Proportion of patients with T2DM with at least an eye exam (ICSO: 95.09.1 or 95.02, or a record of an
ophthalmic visit ICSO: 89.7 or 89.01 or 89.07 or 89.03, with specialty code 034), during the year
Proportion of patients with hypertension with at least an eye exam (ICSO: 95.09.1 or 95.02, or a record of
an ophthalmic visit ICSO: 89.7 or 89.01 or 89.07 or 89.03, with specialty code 034), during the year
https://doi.org/10.1371/journal.pone.0188377.t002
Monitoring compliance with standards of care for chronic diseases in Italy
PLOS ONE | https://doi.org/10.1371/journal.pone.0188377 December 12, 2017 5 / 18
coding system, which is mapped to the Anatomical Therapeutic Chemical classification sys-
tem (ATC);
• Outpatient services registry (OUTPAT) is a list of outpatient activities dispensed by the
healthcare system free of charge or upon co-payment, among which specialist encounters
(with no diagnostic code), laboratory or instrumental or bio-imaging diagnostic tests (with-
out results), recorded with a specific Italian coding system
Within a LHU, all the tables above can be linked with each other at the individual level,
using the national fiscal identifier as a common key. Collection of IAD tables is mandatory by
national law.
Primary care medical records. The National College for General Practitioners (SIMG) is
the national scientific society of General Practitioners (GPs) in Italy. SIMG has trained the
GPs to improve the quality of recording in their medical records. In this type of medical rec-
ords every visit is recorded and all diagnoses, prescriptions and measurements are recorded as
part of a general practitioner’s daily practice. More than 900 members of SIMG use the same
clinical software and share their de-identified medical records in Health Search, a database
which is regularly used for epidemiological, public health and health services research [2, 4, 7,
8]. The GP’s belonging to the sample of this study were all participating in Health Search.
Data collection
A script was developed by SIMG to automatically query the medical records of the 25 GPs.
The script first identified all subjects in charge to the GP at 1st January 2012. Then it computed
variables estimating compliance with the standards of care during 2012 for each subject.
Finally it applied validated algorithms to detect whether subjects had one or more of the dis-
eases under study [4].
All the IAD data available to the healthcare system on the same population was extracted
from the LHUs, using TheMatrix. TheMatrix is an open source software tool that simplifies
the execution of personalized scripts on csv data [9].
Personal identifiers were pseudonymized at extraction, using the same encryption key, and
all the data was automatically transmitted to the National Research Council (CNR), which had
been granted permission to store and process this data. Investigators from Agenzia regionale
di sanità della Toscana (ARS) developed a script to compute the study variables from IAD
data, and CNR ran it on the IAD data. Finally, CNR linked the analytical dataset and medical
records at individual level and transmitted the resulting dataset to ARS for statistical analysis.
One of the GPs from Lombardy was on leave in 2012 and was therefore discarded from the
study after data collection.
Study variables
Case-finding algorithms to identify patients with T2DM, hypertension and IHD from MR
were selected based on a previous validation study. This study proved that the case-finding
algorithms of the three diseases all had almost perfect positive predictive value [4]. Since popu-
lation prevalence estimated with those algorithms is very high, sensitivity must be very high as
well [3]. For this reason, in this study we used the lists of patients detected by MR as a perfect
identification of the true lists of patients who should comply with the recommendations in
Table 1. Case-finding algorithms to identify patients from IAD used a combination of diagno-
sis from hospital discharge records, disease-specific exemptions from copayment, and utiliza-
tion of treatments: to detect patients who had the disease at 1st January 2012, data from
HOSP, EXE and DRUGS were collected for the previous, respectively, 4, 3 and 2 years. These
Monitoring compliance with standards of care for chronic diseases in Italy
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algorithms are described in detail in S1 Table. Sensitivity and positive predictive values of
those algorithms were estimated in a separate study [5].
Compliance was defined similarly across the two data sources. The patient was considered
to be compliant with a treatment if at least two records of the treatment with different dates
were found in 2012, and compliant with a recommended diagnostic test if at least one pre-
scription for that test was found in 2012, except in the case of glycated hemoglobin where two
records were requested.
As discussed in the Introduction, both IAD and MR have imperfect sensitivity in detecting
compliance. For each standard of care we analysed three different variables: compliance as
measured by IAD, compliance as measured by MR, compliance as measured by either source
(EITHER).
Measures of compliance
For each person in the study population we had variables estimating whether the person had
each disease and variables estimating whether the person was compliant with each standard,
all computed both from IAD and from MR. We were therefore able to compare three ways of
estimating the proportion of patients with each disease who were compliant with each stan-
dard: based on IAD only, based on MR only, and based on either IAD or MR. When based on
IAD only: both patients and compliance were estimated from IAD. This is mainly the perspec-
tive from the national and regional NHS policy maker, who have only IAD data available.
When based on MR only, the patients and compliance both are estimated from MR. This is
usually the perspective of the GP when evaluating his/her own practice. A third perspective
takes the whole set of services used by the population into account. This perspective, the true
value of compliance with the standard of care in the population with the disease, is often lack-
ing. With our data we could estimate this measure by selecting the patients with the disease
from MR and the compliance from either MR or IAD: MR is the best possible population of
patients, because it is a gold standard, and “either MR or IAD” is the best possible variable for
compliance, because the two data sources compensate each other’s incompleteness. We refer
to this as the “best possible estimate”.
Quality governance scenarios
We considered two scenarios of quality governance where the results of our comparison can
be useful, as shown in Table 2.
In the local scenario, local or regional decision makers discuss quality of care with GPs with
a focus on quality improvement. In this scenario, we hypothesised that the clusters of interest
were the clusters of patients assisted by a same GP, and the measures to be compared were the
point of view of the healthcare system (the proportion of those who compliant according to
IAD among those who have the disease according to IAD) with the point of view of GP’s (the
proportion of those who are compliant according to MR among those who have the disease
according to MR).
In the central scenario, regional or national decision makers discuss quality of care, respec-
tively, with local or regional decision makers with a focus on quality monitoring. In this sce-
nario we hypothesised that the clusters of interest were the clusters of patients assisted by the
same LHU, and the measures to be compared were the point of view of the healthcare system
(the proportion of those who are compliant according to IAD among those who have the dis-
ease according to IAD) with the best estimate of the true value of the indicators (the propor-
tion of those who are compliant according to either IAD or MR, among those who have the
disease according to MR).
Monitoring compliance with standards of care for chronic diseases in Italy
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Data analysis
For each disease we identified the list of patients who had the disease according to IAD, and
using MR as a gold standard we marked those whose condition was unconfirmed by MR: this
way we created both the list of patients that IAD correctly identified as having the disease, and
the list of patients that IAD only classified as having the disease. Moreover, we identified from
MR patients that were not detected by IAD. We computed the excess of true cases with respect
to those in IAD who were confirmed by MR, using the formula
ðN patients who really had the disease=N patients that IAD correctly identified as having the diseaseÞ  1
Since we didn’t have a gold standard for compliance, we computed Cohen’s kappa between
the compliance detected by MR and the compliance detected by IAD. Concordance was cate-
gorized as “Poor” (<0.20), “Fair” (0.21–0.40), “Moderate” (0.41–0.60), “Good” (0.61–0.80),
“Very good” (0.81–1.00) [10]. Moreover, we computed the percentage of the population com-
pliant in one source that overlapped with those compliant in the other source. We computed
the increase in the compliant population when we added MR to IAD, using the formula
ððN compliant according to either IAD orMRÞ=N compliant according to IADÞ  1
For each recommendation and each cluster (GP or LHU), the different measures to com-
pute the proportion of patients who were compliant to the recommendation (Listed in the last
two rows of Table 2) were standardised per age and gender, using as a standard the weights
listed in S2 Table, which were computed from the age and gender distribution obtained from
MR.
We estimated average difference between the indicators computed by pairs of sources on
each cluster and tested significance. Estimates were obtained by fitting logistic models on a
dataset with a record per patient and source, with the source of information (IAD vs MR, or
IAD versus EITHER) as a dependent variable. Variance was estimated by clustering the obser-
vations on the same subject. Models were adjusted per LHU, age band and gender, with inter-
action between source and cluster variable (GP or LHU). In a sensitivity analysis, to test the
robustness of the “best estimated” with respect to the assumption that patients detected by
IAD but unconfirmed by MR didn’t have the disease, we repeated the analysis and included
the patients unconfirmed by MR in the “best estimate”.
For each disease, to assess whether patients detected by IAD (both confirmed by MR and
unconfirmed) were representative of the population whose disease was assessed in MR, we
estimated the difference between compliance computed on patients correctly detected by IAD
Table 2. Scenarios of quality governance where the results from this study can be used. IAD: administrative databases, MR: primary care medical rec-
ords, EITHER: either among IAD or MR.
Quality governance scenarios Local Central
Activity Quality improvement Quality monitoring
Comparison Actors Local decision-
makers
GPs Local (regional) decision-
makers
Regional (national) decision-
makers
Clusters Patients assisted by the
same GP
Patients assisted by the same LHU (region)
Point of view Healthcare system GP Healthcare system Best estimate
Data source used to detect patients IAD MR IAD MR
Data source used to assess
compliance
IAD MR IAD EITHER
https://doi.org/10.1371/journal.pone.0188377.t003
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and, respectively, patients not detected by IAD and patients only detected by IAD. In this anal-
ysis compliance was estimated with EITHER, and was adjusted per LHU, age and gender.
Ethics
Permission to perform record linkage between pseudonymized administrative data and medi-
cal records was granted by the Italian National Authority for the Privacy regulation. Specifi-
cally, permission was granted to CNR to store and process the data, and to ARS to obtain the
linked individual-level analytical dataset, for statistical analysis.
Results
Study population
Data on 32,688 subjects was collected. The average number of patients per GP was 1,362 (IQ
range: 1,209–1,500).
Comparison of variables detecting diseases
12,673 subjects had at least one of the three diseases according to at least one of the two data
sources. According to IAD, 2,047 subjects had T2DM: only 107 (5%) were patients that IAD
only identified as having the disease, but additional 823 subjects (+40%) were patients having
the disease, according to MR, but not detected by IAD. 8,392 subjects had hypertension
according to IAD: 1,103 (13%) were patients that IAD only identified as having the disease,
and additional 3,573 subjects (+42%) were patients having the disease, according to MR, but
not detected by IAD. 745 subjects had IHD according to IAD: 145 (19%) were patients that
IAD only identified as having the disease, and additional 776 subjects (+ 104%) were patients
having the disease, according to MR, but not detected by IAD. In Fig 1 the number of patients
detected by the two sources for each disease is depicted.
Comparison of variables measuring compliance
On the general population Cohen’s kappa showed very good concordance (from 0.92 to 0.89)
in the four indicators of compliance with therapies. Among diagnostic tests, concordance was
very good (0.84) for microalbuminuria, good (from 0.76 to 0.66) for glycated hemoglobin,
lipid profile and creatinine, moderate (0.44) for ECG and fair (0.27) for eye exams (0.27)
(Table 3). Information provided by MR was almost complete (from 97% to 94%) for compli-
ance with therapies, and was more complete than IAD in all the other indicators except eye
exam (20%) (Table 3). Adding EITHER to IAD increased the measure of compliance by less
than 15% in the case of therapies and of eye exam, from 24% to 32% in microalbuminuria, gly-
cated hemoglobin, creatinine and lipid profile, and more than 50% for ECG.
Comparison of indicators of compliance
Scatter plots of the age-and-gender standardized indicators on the clusters of patients are rep-
resented in Fig 2. The corresponding values are listed in S1 File.
IAD and MR had on average very similar estimates for therapeutic indicators, although for
statins in both T2DM and IHD, and for betablockers in IHD, IAD had a significantly higher
estimate (respectively +4.1, +4.5 and +5.4). The results were confirmed when comparing IAD
with the “best estimate”, and differences were reduced. In the case of diagnostic indicators, the
picture was more complex, with IAD showing higher values than MR and lower values than
the “best estimate”, often significantly. Average difference between IAD and MR was signifi-
cant and higher than 5 percentage points for glycated hemoglobin and eye exam in T2DM.
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Average difference between IAD and “best estimate” was significant in all indicators except
glycated hemoglobin, and in all but microalbuminuria and eye exam (Table 4).
The sensitivity analysis confirmed the results obtained in the comparison between IAD and
the “best estimate”: the estimates changed by around one percentage point (S3 Table).
Representativeness of subpopulations
Indicators in patients not detected by IAD were much lower (from -15.8 to -40.1 percentage
points difference) with respect to indicators in patients correctly detected by IAD in the case of
T2DM, and substantially lower (from -6.7 to -24.6 percentage points difference) in the case of
IHD (Table 3). They were lower in the case of hypertension, too, but less so (from -4.8 to -13.9
percentage points difference). Differences were higher for indicators of therapies. Differences
between patients detected by IAD and confirmed by MR and patients only detected by IAD
were similar but slightly smaller (Table 3).
Discussion
Measures of compliance in the whole population were concordant between MR and IAD in
the case of therapies, less so in the case of diagnostic testing, especially when more complex
tests were considered (ECG and eye exam). Indicators of compliance with therapies showed
low average difference between data sources, although still significant in some cases. Indicators
of compliance with diagnostic monitoring were imbalanced: IAD estimated higher compliance
with respect to MR, and lower compliance with respect to the best possible estimate. This was
the result of a combination of different errors. Patients detected by IAD were not representa-
tive of the true population of patients, especially in the case of T2DM and of therapeutic indi-
cators. Small average differences between the estimates of IAD and the best estimates were
Fig 1. Patients detected by IAD or by MR, for each disease. “Patients that IAD only classified as having the disease” were those detected by IAD, but not
by MR. "Patients that IAD correctly identified as having the disease" were identified by both IAD and MR. “Patients not detected by IAD" were identified by
MR, but not by IAD.
https://doi.org/10.1371/journal.pone.0188377.g001
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partially coincidental and therefore run the risk of not being reproducible in all the regions
and across time.
Interpretation of the findings: Estimating compliance with recommended
therapies and diagnostic tests
This individual-level study showed that the confounding effects anticipated in the limitations
of the ecological study were indeed playing an important role in the estimate of indicators per-
formed on IAD.
The effects of different misclassifications (of patients and of compliance) were balanced
in the case of therapies, because concordance between MR and IAD was high, and MR was
almost complete; therefore, the absence from the denominator of the indicator of those
patients who were not detected by IAD, who had lower compliance, compensated the small
overall underestimation of the compliance. A small contribution to the balance was also pro-
vided by the comparatively small share of patients that IAD only classified as having the dis-
ease, who had similar compliance profile as patients not detected by IAD.
As expected, measures of compliance obtained from IAD and MR were less concordant in
the case of diagnostic tests, and compliance measured by IAD was lower. The combination
of errors produced both balanced and imbalanced results. In the case of glycated hemoglobin
test, in the patients not detected by IAD the indicator was less that 40 percentage points lower
than in patients correctly identified by IAD as having the disease and the overall agreement
between the administrative and “best estimate” was due to underestimation of compliance on
the patients detected by IAD. However there was an important imbalance between IAD and
MR estimate in T2DM patients. In recent, similar validation studies of estimates of measures
of performance on diabetic patients from administrative databases from the United States,
similar mixed effects were observed [11, 12].
Table 3. Comparison of compliance measured by IAD, by MR or by either of the two data sources, on the whole population. Difference in the value
of indicators between the patients that IAD correctly identified as having the disease and patients not detected by IAD (ND), and between the patients that IAD
correctly identified as having the disease and patients that IAD only classified as having the disease (FD). Difference was computed using EITHER for compli-
ance, and adjusting per age, gender and LHU. Standards are listed in decreasing order of Cohen’s kappa.
Difference in indicators between the patients
that IAD correctly identified as having the
disease and patients not detected by IAD
(ND), and between the patients that IAD
correctly identified as having the disease and
patients that IAD only classified as having the
disease (FD)
Recommendation Cohen’s K Percentage of the population compliant
in one source that overlaps with those
compliant in the other source.
Percentage increase in
compliance when
adding EITHER to IAD
T2DM Hypertension IHD
Of those compliant
according to IAD
Of those compliant
according to MR
ND FD ND FD ND FD
Statins 0.92 97.0% 89.4% +11.5% -19.3 -18.5 -24.6 -18.2
Betablockers 0.91 95.7% 88.8% +12.1% -21.9 -16.2
ACE inhibitors 0.90 96.6% 88.0% +13.2% -11.7 -6.9
Antithrombotics 0.89 94.5% 86.6% +14.7% -15.0 -12.8
Microalbuminuria 0.84 93.3% 78.1% +26.2% -38.6 -29.0 -13.3 -16.8
Glycated hemoglobin 0.76 77.3% 76.6% +23.7% -40.1 -32.8 -4.8 -10.3 -6.7 -4.2
Lipid profile 0.73 91.0% 73.9% +32.1% -26.6 -13.5 -13.9 -16.3 -9.1 -2.2
Creatinine 0.66 84.2% 74.7% +28.5% -15.8 -13.9 -7.7 -13.9
ECG 0.46 52.1% 50.8% +50.5% -5.9 -12.3 -6.5 -6.3
Eye exam 0.27 20.1% 62.5% +12.1% -20.1 -14.8
https://doi.org/10.1371/journal.pone.0188377.t004
Monitoring compliance with standards of care for chronic diseases in Italy
PLOS ONE | https://doi.org/10.1371/journal.pone.0188377 December 12, 2017 11 / 18
Fig 2. Scatter plots comparing age-and- gender standardised measures of compliance with standards of care, in the two
governance scenarios. In the Local governance scenario the 24 clusters of patients of the same GP are measured by IAD on the Y-
axis and MR on the X-axis. In the Central governance scenario the 5 clusters of patients in the same LHU are measured by IAD on the
Y-axis and best estimate (proportion of patients detected by MR with are compliant according to EITHER) on the X-axis.
https://doi.org/10.1371/journal.pone.0188377.g002
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In the scatterplots in Fig 2, IAD measured a very low compliance with Microalbuminuria
and Lipid profile indicators on a GP, in the patients of all the three diseases. Those patients
were all assisted by the same GP (see S1 File), and it is therefore possible that some local issue,
such as the absence of a nearby laboratory contracted with the NHS, or a systematic mistake
made by a local laboratory in coding those specific exams, was at the root of this finding. As a
consequence, in the same indicators IAD measured lower compliance than MR in the LHU
of this GP. In the same figure, IAD measured low compliance with Statins, Betablockers and
Antithrombotics treatment in patients with IHD of a GP. The GP was the same in the three
cases, but different with respect to the outlier GP in the indicators of compliance with diagnos-
tic recommendations (see S1 File). The outlier GP of therapeutic indicators in IHD was also
the one with lowest number of IHD patients detected by IAD (15 patients). In this case, chance
may have played a role in concentrating among the half of the patients of this GP detected by
IAD a higher socio-economic status, that may have resulted in a higher proportion of such
patients purchasing drugs out-of-pocket. As an alternative explanation, the local pharmacy
may have transmitted incomplete or corrupted records to the LHU.
Consequences on the use of Italian administrative data in a systematic
quality monitoring and improvement strategy
In a quality monitoring strategy IAD is a reliable tool for signalling purposes: when IAD
detects either an excellent or a poor performance in a cluster of patients, according to our data
it is very likely that the observation is correct, particularly in the case of compliance with thera-
peutic standards, and with yearly laboratory diagnostic tests.
However, we found that a combination of mutually balancing misclassifications is at the
root of the similarity between IAD results and our best estimate of the true compliance in the
patients with a diagnosed chronic disease, especially in the case of diagnostic recommenda-
tions. Specific caution should be taken in interpreting coverage of the twice-yearly glycated
hemoglobin test in diabetic patients. Likewise, the measures of compliance with annual eye
exam in diabetics, and annual ECG in hypertensive and IHD patients look fragile.
This has slightly different implications for a “local” quality improvement rather than a “cen-
tral” quality monitoring scenario.
Table 4. Average difference between the indicators computed in pairs of sources. On the left (local governance scenario): comparison between MR
and IAD. On the right (central governance scenario): comparison between IAD and “best estimate”. For each indicator the p-value of the significance of the dif-
ference is shown.
Local governance scenario Central governance scenario
T2DM Hypertension IHD T2DM Hypertension IHD
Indicator Δ p Δ p Δ p Δ P Δ p Δ P
Therapeutic Statins 4.1 <0.001 4.5 <0.05 3.3 <0.001 3.6 <0.05
Betablockers 5.4 <0.001 3.3 <0.05
ACE inhibitors 2.2 0.152 0.0 0.992
Antithrombotics 1.3 0.345 -0.5 0.691
Diagnostic Microalbuminuria -0.1 0.931 -0.2 0.543 -3.4 <0.001 -2.3 <0.001
Glycated hemoglobin 8.9 <0.001 2.2 <0.001 3.0 <0.05 -0.1 0.929 -0.0 0.950 -1.1 0.366
Lipid profile -3.0 <0.001 -3.9 <0.001 -2.9 0.074 -6.3 <0.001 -7.2 <0.001 -6.9 <0.001
Creatinine 0.8 0.402 -1.2 <0.05 -5.7 <0.001 -7.4 <0.001
ECG 0.1 0.891 1.2 0.539 -7.7 <0.001 -14.1 <0.001
Eye exam 7.5 <0.001 -4.7 <0.001
https://doi.org/10.1371/journal.pone.0188377.t005
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In a local scenario the main actors are, on the one hand, the local (or regional) decision-
makers for the organization of healthcare for chronic diseases and, on the other, the GPs. The
main objective is promoting appropriateness in healthcare for chronic diseases, that is, sup-
porting the role of primary care as the main driver, in close collaboration with specialist care
[1]. Thanks to IAD, decision makers have the possibility of producing estimates of compliance
across a range of GPs. While this sort of comparison is in itself very informative, it is clear
from our validation that it is not precise enough to provide a reliable ranking of the perfor-
mance of GPs, nor to support quality-based payment systems, such as a pay-for-performance
scheme. Rather it should be taken as the starting point for quality improvement initiatives,
such as a more detailed audit of quality based on medical records. Clusters of patients with low
compliance, as signalled by IAD, must be analysed in conjunction with context information,
such as local issues in data quality, accessibility to local NHS facilities for diagnostic tests, and
possible drive of local specialist healthcare providers towards replacing, rather than supple-
menting, primary care, sometimes implying out-of-pocket purchase of care. All those elements
can provide input to action for local decision-makers. Clusters with high compliance, in turn,
must be critically analysed: if patients with mild forms of chronic diseases are not appropri-
ately followed-up, they will remain undetected by IAD, which will therefore measure higher
compliance only on the more severe patients, thus providing a falsely reassuring picture. This
is likely to be associated with clusters where IAD detects low prevalence. Aside from those
extremes, quality governance at the local levels should focus on an integrated interpretation of
IAD and MR data, which are both available to the actors.
In a central scenario the main actors are all decision-makers for the organization of health-
care system, at different levels: local vs regional, or regional vs national. The main objective is
monitoring quality of healthcare and making comparisons between the different geographical
entities to assure equity in quality of care amongst the whole Italian population. Integrated
analysis of IAD and MR is not possible in this scenario, therefore context for interpretation of
signals from IAD must be carefully built in collaboration with local decision-makers, who can
provide crucial context information, in particular findings from local analysis of MR. Several
resources are available to inform this assessment: SIMG produces a yearly report comparing
compliance with standards of care across Italian regions estimated from MR of a sample of
GPs belonging to the Health Search network [13], and survey data are produced every five
years by the National Institute of Statistics, estimating access to NHS specialist facilities [14].
Developments
The proportion of patients not detected by IAD was substantial, and this finding has conse-
quences that go beyond the objective of this study. A more extensive treatment of this issue
can be found in a separate study.[5]
Routine data-linkage between administrative data and key elements from primary care
medical records, such as diagnosis of a chronic disease and compliance with standards of care,
would critically improve the quality governance of primary care. Local initiatives have been
initiated to this respect, such as the SOLE network in Emilia-Romagna [1].
Analytical calibration methods that include the results from this validation study, as well as
aggregated measures produced by SIMG and the National Institute of Statistics, could be
developed to improve estimates produced by IAD.
Implications for the use of the indicators in studies of impact
Indicators of compliance with standards of care can be used to evaluate the impact of innova-
tive strategies [15, 16, 17]. Our results support overall this use of the indicators, provided a
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difference-in-differences design is adopted, and the impact is measured across a short time
span, so that it can be assumed that misclassification does not change differentially across
exposed and non exposed to the intervention. If this is not possible, elements that may imbal-
ance misclassification across exposed and non-exposed, or across time, need to be discussed in
the limitations of the study.
Permission to perform record linkage was an extraordinary result
This study was made possible by an explicit permission of the Italian National Authority for
the Privacy regulation, which allowed individual-level record linkage between IAD and MR on
a large sample of patients. It is encouraging that such permission was granted, and routes for
expedited permission should be created, especially for validation studies of administrative
data. Indeed, this would allow rapid generation of evidence crucial for public health and health
system governance in a transparent and legal manner.
Limitations
The variable that we used as a “best estimate” of compliance may have overestimated the true
compliance, as GP drug prescriptions may have not been filled in, and GP test orders may
have not been performed in reality. The first effect is however likely to be small, as a second
prescription is required for the patient to be compliant, according to the algorithm we adopted
in our computations. Moreover, the concordance we observed between MR and IAD data was
very high when measuring compliance with therapies (Table 3).
The indicators of compliance with a recommended therapy adopted by the MATRICE
panel of experts (Box 1) use a simple rule (at least two records in a year). This rule is easy to
implement across different data sources, such as IAD and MR, and has been used since 2004
to compute similar indicators in the Quality and Outcome Framework of the National Health
System of the United Kingdom [18,19], which have been proven to be effective for the pur-
poses of quality monitoring and improving [18]. However, an indicator computed with this
rule does not measure true adherence to therapy.
In our analysis we assumed that patients classified as having a disease by IAD, but uncon-
firmed by MR, were in fact without the disease. To assess robustness of results to this assump-
tion, we first showed that the number of persons detected by IAD and unconfirmed by MR is
small, in comparison to the number of people detected by MR, especially in the case of T2DM.
Moreover, we tested the impact of the assumption on the "best estimate" in a sensitivity analy-
sis, and showed that the difference is around one percentage point, which leaves unchanged
the interpretation of our findings.
Conclusion
IAD overestimated the percentage of patients compliant with therapeutic standards by less
than 6 percentage points, and underestimated the percentage of patients compliant with
diagnostic standards by a maximum of 14 percentage points. Therefore, both discussions
at local level between GP’s and local health unit managers and discussions at central level
between national and regional policy makers can be informed by indicators of compliance
estimated by IAD, which, based on those results, have the ability of signalling critical or
excellent clusters. However, this study found that estimates are partly flawed, because a
high number of patients with chronic diseases are not detected by IAD, patients detected
are not representative of the whole population of patients, and some categories of diagnostic
tests are markedly underrrecorded in IAD (up to 50% in the case of electrocardiograms).
Those results call to caution when interpreting IAD estimates. Audits based on medical
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records, on the local level, and an interpretation taking into account information external
to IAD, on the central level, are needed to assess a more comprehensive compliance with
standards.
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